These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 19779315)
41. [Role of Ca 125 in pelvic masses. Our experience]. Rotondi M; Lauro C; Ammaturo FP; Guerriero V; Rasile M; Panariello S Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):51-4. PubMed ID: 11526720 [TBL] [Abstract][Full Text] [Related]
42. Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. Campbell S Ultrasound Obstet Gynecol; 2012 Sep; 40(3):245-54. PubMed ID: 22911634 [No Abstract] [Full Text] [Related]
43. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Holbert TR Am J Obstet Gynecol; 1994 Jun; 170(6):1699-703; discussion 1703-4. PubMed ID: 8203429 [TBL] [Abstract][Full Text] [Related]
44. Total inhibin is a potential serum marker for epithelial ovarian cancer. Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066 [TBL] [Abstract][Full Text] [Related]
45. [Genetics and ovarian cancer--surveillance of a woman belonging to a family at risk for ovarian cancer]. Isart-Debaud V; Lefranc JP Gynecol Obstet Fertil; 2000 Jan; 28(1):73-5. PubMed ID: 10774120 [No Abstract] [Full Text] [Related]
46. Screening for ovarian cancer. We now need a definitive randomised trial. Urban N BMJ; 1999 Nov; 319(7221):1317-8. PubMed ID: 10567117 [No Abstract] [Full Text] [Related]
48. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136 [TBL] [Abstract][Full Text] [Related]
49. Screening for ovarian cancer. Quinn MA Aust Fam Physician; 2001 Jun; 30(6):530-4. PubMed ID: 11458578 [TBL] [Abstract][Full Text] [Related]
50. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468 [TBL] [Abstract][Full Text] [Related]
51. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Jacobs I Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805 [No Abstract] [Full Text] [Related]
53. [Mass-screening for ovarian cancer by means of transvaginal ultrasonography--study on size of ovary to select subjects requiring second screening]. Sato S; Hasuo Y; Ohta S; Maruyama H; Kagiya A; Saito Y Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1173-9. PubMed ID: 1453046 [TBL] [Abstract][Full Text] [Related]
54. [The screening and diagnosis of ovarian cancer]. Zlatkov V; Kostova P Akush Ginekol (Sofiia); 1998; 37(3):54-6. PubMed ID: 10204273 [TBL] [Abstract][Full Text] [Related]
58. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Bast RC Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970 [TBL] [Abstract][Full Text] [Related]
59. Adnexal masses: when to observe, when to intervene, and when to refer. Falcone T Obstet Gynecol; 2010 Apr; 115(4):680-681. PubMed ID: 20308824 [No Abstract] [Full Text] [Related]